Research Training in Pediatric Oncology

儿科肿瘤学研究培训

• 批准号: 10646386
• 负责人: SCOTT A ARMSTRONG
• 金额: $ 44.59万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-13 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10646386
• 关键词: Pediatric Oncology; Research Training

PROJECT SUMMARY/ABSTRACT This is a competitive renewal application for training grant support in pediatric oncology. The goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population. To accomplish this goal we have engaged a diverse and outstanding training faculty that embraces multiple areas of basic (“wet bench”), translational and clinical research. This experienced and highly accomplished group includes members of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Boston Children's Hospital (BCH), and additional components of the Harvard Medical School (HMS). Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The T32 program provides training in oncology research at the postdoctoral level for 8 trainees, selected from the combined DFCI-BCH pediatric hematology/oncology fellowship program, who are in their second, third and fourth years of training. These fellows spend on average five to six years in a protected training environment with limited clinical responsibilities, and the proposed T32 renewal would continue to support three years of that training. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 45 years the DFCI-BCH fellowship program has trained over 200 individuals, many of whom are leaders of academic pediatric hematology/oncology programs. Continued T32 support will ensure the training of investigational pediatric oncologists, whose research will contribute immeasurably to the understanding and management of childhood cancers.

项目总结/摘要 这是儿科肿瘤学培训补助金支持的竞争性更新申请。T32的目标 该计划是培养医生谁将是未来的学术领导人在基础和/或临床儿科 肿瘤学研究，世卫组织将致力于减少儿科人群的癌症负担。完成 这一目标，我们已经聘请了多元化和优秀的培训教师，包括多个领域的基本 （“湿台”），转化和临床研究。这个经验丰富、成就卓著的团队包括： Dana-Farber癌症研究所（DFCI）儿科肿瘤学系的成员， 波士顿儿童医院（BCH）的儿科血液学/肿瘤学，以及 哈佛医学院。在挑选学员时特别强调对学员的密切指导 导师和在他们的研究过程中持续的监督。T32项目提供肿瘤学培训 在博士后水平的研究，8名学员，从联合DFCI-BCH儿科 血液学/肿瘤学奖学金计划，谁是在他们的第二，第三和第四年的培训。这些 研究员平均在受保护的培训环境中度过五到六年， T32的更新将继续支持三年的培训。的 该计划致力于确定和支持最有前途的研究员，包括少数民族候选人。 在过去的45年里，DFCI-BCH奖学金计划已经培训了200多名个人，其中许多人是 儿科血液学/肿瘤学学术项目的领导者。持续的T32支持将确保培训 研究儿科肿瘤学家，他们的研究将有助于不可估量的理解， 儿童癌症的管理。

项目成果

A predictive microfluidic model of human glioblastoma to assess trafficking of blood-brain barrier-penetrant nanoparticles.

• DOI: 10.1073/pnas.2118697119
• 发表时间: 2022-06-07
• 期刊: Proceedings of the National Academy of Sciences of the United States of America
• 影响因子: 11.1

Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.

• DOI: 10.1038/s41588-018-0191-z
• 发表时间: 2018-09
• 期刊: Nature genetics
• 影响因子: 30.8
• 作者: Durbin AD;Zimmerman MW;Dharia NV;Abraham BJ;Iniguez AB;Weichert-Leahey N;He S;Krill-Burger JM;Root DE;Vazquez F;Tsherniak A;Hahn WC;Golub TR;Young RA;Look AT;Stegmaier K
• 通讯作者: Stegmaier K

Trends in conditional survival and predictors of late death in neuroblastoma.

神经母细胞瘤条件生存的趋势和晚期死亡的预测因素。

• DOI: 10.1002/pbc.28329
• 发表时间: 2020
• 期刊: Pediatric blood & cancer
• 影响因子: 3.2
• 作者: Olsen,HannahE;Campbell,Kevin;Bagatell,Rochelle;DuBois,StevenG
• 通讯作者: DuBois,StevenG

FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits.

• DOI: 10.1158/0008-5472.can-22-0671
• 发表时间: 2022-09-02
• 期刊: Cancer research
• 影响因子: 11.2

The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor.

• DOI: 10.1002/pbc.28559
• 发表时间: 2020-10
• 期刊: Pediatric blood & cancer
• 影响因子: 3.2
• 作者: Liu KX;Collins NB;Greenzang KA;Furutani E;Campbell K;Groves A;Mullen EA;Shusterman S;Spidle J;Marcus KJ;Weil BR;Weldon CB;Frazier AL;Janeway KA;O'Neill AF;Mack JW;DuBois SG;Shulman DS
• 通讯作者: Shulman DS